Catalyst
Slingshot members are tracking this event:
FDA Announces Acceptance of NDA for Puma Biotech's (PBYI) PB272 (Neratinib) in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PBYI |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 20, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Nda, Fda, Accepted For Review, Pb272, Neratinib, Extended Adjuvant Treatment, Her2-positive, Early Stage, Breast Cancer
